• Sulfaphenazole: Precision Competitive CYP2C9 Inhibitor fo...

  2026-01-30

  Sulfaphenazole is a highly specific competitive CYP2C9 inhibitor with a Ki of 0.3 ± 0.1 μM, widely used to dissect cytochrome P450-mediated drug metabolism and vascular endothelial function. Its selectivity and potency make it a benchmark tool for pharmacogenetics and adverse drug reaction studies. APExBIO’s Sulfaphenazole (C4131) enables reproducible and mechanistic research workflows.

• Epalrestat at the Nexus of Diabetic Complication and Neur...

  2026-01-30

  This thought-leadership article provides translational researchers with a comprehensive exploration of Epalrestat’s mechanistic roles as an aldose reductase inhibitor, focusing on its dual impact in diabetic complication models and emerging neuroprotection paradigms via KEAP1/Nrf2 pathway activation. Integrating recent evidence—including pivotal findings from Jia et al.—the article delivers actionable strategic guidance for experimental workflow design and positions Epalrestat (SKU B1743, APExBIO) as an advanced biochemical tool for oxidative stress, diabetic neuropathy, and Parkinson’s disease research.

• Fluconazole: Mechanistic Benchmarks for Antifungal Suscep...

  2026-01-29

  Fluconazole is a triazole-based antifungal agent that inhibits fungal cytochrome P450 enzyme 14α-demethylase, disrupting ergosterol biosynthesis in pathogenic fungi. This article details atomic, verifiable findings on its mechanism, susceptibility benchmarks, and translational limits in Candida albicans research. It provides structured guidance for accurate antifungal testing and drug resistance modeling.

• Abiraterone Acetate: Potent CYP17 Inhibitor for Prostate ...

  2026-01-29

  Abiraterone acetate is a 3β-acetate prodrug and a highly selective CYP17 inhibitor that irreversibly suppresses androgen biosynthesis. Its high purity and potency make it a gold-standard tool in castration-resistant prostate cancer (CRPC) research. This article provides atomic, verifiable claims and benchmarks for scientific workflows.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Next-Generation Reporter...

  2026-01-28

  Discover the scientific advances behind EZ Cap™ Cy5 EGFP mRNA (5-moUTP), a fluorescently labeled, immune-suppressive reporter mRNA optimized for high-fidelity mRNA delivery, translation efficiency assays, and in vivo imaging. This article uniquely explores mechanistic details and future directions in mRNA research, setting a new standard for gene regulation studies.

• Empowering Cell Assays with EZ Cap™ Cy5 EGFP mRNA (5-moUT...

  2026-01-28

  This article provides biomedical researchers and lab technicians with scenario-driven guidance on integrating EZ Cap™ Cy5 EGFP mRNA (5-moUTP) (SKU R1011) into cell viability, proliferation, and cytotoxicity workflows. Leveraging evidence-backed Q&A, it demonstrates how this capped, immune-evasive, and dual-fluorescent mRNA enhances reproducibility, sensitivity, and data integrity in challenging experimental contexts.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Advanced mRNA Delivery &...

  2026-01-27

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) redefines mRNA delivery and translation efficiency assays by combining robust immune evasion, dual fluorescence for real-time tracking, and enhanced stability. Its Cap 1 capping and innovative modifications empower high-fidelity gene regulation studies, streamlined troubleshooting, and seamless in vivo imaging—making it indispensable for modern molecular biology labs.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Benchmarking Capped Repo...

  2026-01-27

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) is a dual-fluorescent, Cap 1-structured synthetic mRNA optimized for high-efficiency delivery, immune evasion, and robust in vitro as well as in vivo imaging. This capped mRNA enables quantitative gene regulation studies and translation efficiency assays with minimal innate immune activation. APExBIO’s R1011 product sets a reference standard for fluorescently labeled mRNA in functional genomics and delivery research.

• (S)-Mephenytoin (SKU C3414): Reliable CYP2C19 Substrate f...

  2026-01-26

  (S)-Mephenytoin (SKU C3414) offers biomedical researchers a robust, validated CYP2C19 substrate for in vitro drug metabolism and pharmacokinetic studies. This article explores real-world laboratory scenarios, highlighting how (S)-Mephenytoin addresses challenges in experimental design, data interpretation, and vendor reliability, empowering reproducible and translational results in cytochrome P450 research.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Capped mRNA for Efficien...

  2026-01-26

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) is a synthetic, capped messenger RNA designed for robust gene regulation and translation efficiency assays. With a Cap 1 structure and Cy5 fluorescent labeling, it enables high-fidelity mRNA delivery, immune evasion, and real-time imaging, making it a benchmark tool for advanced cell and in vivo studies.

• (S)-Mephenytoin: Benchmark CYP2C19 Substrate for Organoid...

  2026-01-25

  Harness the reproducibility and translational power of (S)-Mephenytoin for CYP2C19-driven drug metabolism research in hiPSC-derived intestinal organoids. This guide details optimized workflows, advanced use-cases, and actionable troubleshooting tips to elevate your pharmacokinetic studies beyond legacy models.

• Abiraterone acetate (SKU A8202): Reliable CYP17 Inhibitio...

  2026-01-24

  This article offers a scenario-driven, evidence-based guide to deploying Abiraterone acetate (SKU A8202) in cell viability and androgen receptor assays, addressing workflow challenges from solubility to model selection. With a focus on data-backed reliability and transparency, it empowers biomedical researchers to achieve reproducible, mechanistically relevant insights in prostate cancer studies.

• Abiraterone Acetate: CYP17 Inhibitor Workflows in Prostat...

  2026-01-23

  Abiraterone acetate, a 3β-acetate prodrug of abiraterone, is redefining castration-resistant prostate cancer (CRPC) research by enabling robust and reproducible CYP17 inhibition in translational models. This guide details optimized experimental workflows, advanced applications, and troubleshooting strategies to maximize scientific output using APExBIO’s high-purity Abiraterone acetate.

• Abiraterone Acetate and the Evolution of Translational Pr...

  2026-01-23

  This thought-leadership article explores the transformative role of Abiraterone acetate—a potent, irreversible CYP17 inhibitor and 3β-acetate prodrug of abiraterone—in advancing translational prostate cancer research. Integrating mechanistic insight, critical appraisal of patient-derived 3D spheroid models, and strategic experimental guidance, it empowers researchers to optimize androgen biosynthesis inhibition studies. Drawing on recent literature and the latest model innovations, the article provides actionable recommendations for harnessing Abiraterone acetate in cutting-edge workflows, while situating APExBIO’s highly pure offering at the forefront of the field.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Cap 1 Capped, Fluorescen...

  2026-01-22

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) is a Cap 1-capped, fluorescently labeled reporter mRNA optimized for delivery, translation efficiency, and in vivo imaging. This product offers robust immune evasion, enhanced stability, and dual fluorescence capabilities, making it ideal for gene regulation and mRNA assay workflows.

328 records 15/22 page Previous Next First page 上5页 1112131415 下5页 Last page